SCHEMBL7511275

SCHEMBL7511275

O=Cc1ccc(-c2nc3cc(Cl)c(Cl)cc3n2Cc2ccc3ccccc3c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.53
RHEB Q15382 1/20 0.51
BRD4 O60885 1/20 0.51
VDR P11473 1/20 0.49
GAA P10253 2/20 0.46
MGAM O43451 1/20 0.46
SI P14410 1/20 0.46
MGAM2 Q2M2H8 1/20 0.46
ALDH1A1 P00352 5/20 0.44
HTT P42858 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
DCTPP1 Q9H773 3/20 0.44
KDM4E B2RXH2 2/20 0.44
LMNA P02545 2/20 0.44
CNR2 P34972 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TP53 P04637 4/20 0.43
MAPT P10636 2/20 0.43
PDE6D O43924 2/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7512060 0.90 RHEB (0.56) KCNH2RHEBBRD4GAAMGAM
SCHEMBL7520505 0.89 KCNH2 (0.65) KCNH2RHEBBRD4GAAMGAM
SCHEMBL7516898 0.84 RHEB (0.43) KCNH2RHEBBRD4GAAMGAM
SCHEMBL7525385 0.83 MGAM (0.69) KCNH2RHEBBRD4GAAMGAM
SCHEMBL7525388 0.83 MGAM (0.69) KCNH2RHEBBRD4GAAMGAM
SCHEMBL7520753 0.82 KMT2A (0.58) KCNH2BRD4GAAMGAMSI
SCHEMBL7512243 0.81 BRD4 (0.60) KCNH2RHEBBRD4GAAMGAM
SCHEMBL7517579 0.79 KDM4E (0.59) KCNH2RHEBBRD4GAAMGAM
SCHEMBL7520453 0.79 DRD2 (0.61) KCNH2RHEBBRD4ALDH1A1DCTPP1
SCHEMBL7514629 0.77 KCNH2 (0.46) KCNH2RHEBBRD4GAAMGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 KCNH2 4780/4885RHEB 1710/4885BRD4 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.